ZBIO Stock Overview
A clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Zenas BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.05 |
| 52 Week High | US$26.25 |
| 52 Week Low | US$8.33 |
| Beta | 0 |
| 1 Month Change | -12.07% |
| 3 Month Change | -41.37% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -44.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.0% | 2.1% | 2.8% |
| 1Y | n/a | -3.8% | 24.5% |
Return vs Industry: Insufficient data to determine how ZBIO performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ZBIO performed against the US Market.
Price Volatility
| ZBIO volatility | |
|---|---|
| ZBIO Average Weekly Movement | 13.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ZBIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ZBIO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 115 | Lonnie Moulder | zenasbio.com |
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody.
Zenas BioPharma, Inc. Fundamentals Summary
| ZBIO fundamental statistics | |
|---|---|
| Market cap | US$407.46m |
| Earnings (TTM) | -US$128.97m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.3x
P/E RatioIs ZBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZBIO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$110.40m |
| Gross Profit | -US$110.40m |
| Other Expenses | US$18.57m |
| Earnings | -US$128.97m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.09 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ZBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 23:53 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zenas BioPharma, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Yatin Suneja | Guggenheim Securities, LLC |
| Matthew Caufield | H.C. Wainwright & Co. |